Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The proteolytic enzymes of the coagulation and fibrinolysis systems as well as others such as
kallikrein
, activated under pathological conditions can be determined directly, without manipulations of the plasmas, with the synthetic chromogenic substrates. With these substrates it is possible to follow the protease activity in
disseminated intravascular coagulation
, during thrombolysis and under other conditions. The lack of absolute substrate specificity makes it imposssible to identify the activated proteases.
...
PMID:Assay with chromogenic substrates of in vivo activated proteases. 14 48
Activation of the
kallikrein
-kinin system, as indicated by increased
plasma kallikrein
and depleted plasma kininogen, prekallikrein, and
kallikrein
inhibitor, was observed in five patients with Rocky Mountain spotted fever. Four of the patients had petechial rashes characteristic of vasculitis. Three patients had alterations in coagulation consistent with
disseminated intravascular coagulation
, although no hemorrhagic syndrome was found. Our data, along with the known physiologic actions of kinins, suggest a possible role for the
kallikrein
-kinin system in the pathophysiology of vasculitis,
disseminated intravascular coagulation
, circulatory shock, and other complications of infection with Rickettsia rickettsii.
...
PMID:Activation of the kallikrein-kinin system in Rocky Mountain spotted fever. 30 54
Masugi nephritis was induced in dogs in which platelet count, fibrinogen, antithrombin activity, plasma prekallikrein and immediate plasmin inhibitors were coincidentally decreased immediately after the injection of nephrotoxin serum. It was found that the grade of decrease of
urinary kallikrein
excretion following these immediate reactions were parallel with the grade of renal damages. By the pretreatment with heparin or the
defibrination
with snake venom, however, the histological findings of Masugi nephritis showed rather severe damage. Based on the consumption of coagulation factors,
kallikrein
, kinin and their inhibitors in the development of this nephritis, it was postulated that inauguration of coagulation and activation of
kallikrein
contributed to the development of glomerulonephritis. The treatment or prevention of this coagulation process with heparin or snake venom, however, gave untoward effects on the pathological process in this experiment.
...
PMID:Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis. 49 36
The titers of components of the
plasma kallikrein
-kinin system have been measured conventionally by their biological functions. The functional assays are, however, antagonized by the presence of inhibitors and/or the absence of potentiators in test samples. Immunologic assays obviate these difficulties. We have developed specific, sensitive and reproducible radioimmunoassays (RIA) for HF and prekallikrein, and have applied these assays to some clinical conditions. Normal pooled human plasma contained approximately 40 microgram of HF and 50 microgram of prekallikrein per ml. RIA were able to measure concentrations of HF and prekallikrein as low as 0.1% and 0.3% that of normal pooled plasma respectively. A good correlation existed between titers measured by clotting and radioimmunoassays among 40 normal subjects (correlation co-efficient = 0.82 for HF and 0.71 for prekallifrein). There was no significantly reduced in plasmas of patients with advanced liver cirrhosis or
disseminated intravascular coagulation
(
DIC
) and in cord serums, but they were normal in plasmas obtained after strenuous physical exercise and in plasmas of patients under treatment with warfarin.
...
PMID:Determination of Hageman factor (HG, factor XII) and plasma prekallikrein (Fletcher factor) by radioimmunoassays. 57 61
The results of this paper indicate that cattle infected with B. bovis (argentina) have a markedly altered and activated coagulation system. A degree of thrombin activation occurs due partly to release of thromboplastin-like substances from lysed erythrocytes but due primarily to activation of
kallikrein
by babesial proteases. This produces a hyperfibrinogenaemia, particularly in intact cattle, with soluble fibrin complexes constituting up to one-third of the total fibrinogen concentration. High molecular weight non-coagulable fibrinogen-like proteins are detected terminally but more so in splenectomized cattle. Plasminogen concentration decreases in splenectomized but not intact cattle while low molecular weight fibrinogen degradation products are not easily detected. It is suggested that a hypercoagulable intermediate state with little or no fibrin deposition occurs rather than terminal
disseminated intravascular coagulation
.
...
PMID:Babesia bovis (argentina): observations of coagulation parameters, fibrinogen catabolism and fibrinolysis in intact and splenectomized cattle. 60 70
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen levels have been examined in various clinical conditions. Prekallikrein antigen was measured by a newly developed, specific, and sensitive radioimmunoassay. The assay had no demonstrable cross-reactivity with human
urinary kallikrein
nor, in the species tested, animal plasma prekallikrein. This assay was able to measure
plasma kallikrein
after its biological functions had been inactivated by plasma inhibitors. Normal human pooled plasma contained approximately 50 microgram/ml prekallikrein. Quantitative measurement of plasma prekallikrein was possible for concentrations as low as 0.3% of that of normal pooled plasma. A good correlation (correlation coefficient = 0.71) existed between titers of plasma prekallikrein measured by Fletcher factor clotting assays and radioimmunoassays among 40 normal subjects. Both prekallikrein clotting activity and antigen were significantly reduced in plasmas of patients with advanced hepatic cirrhosis or
DIC
. Prekallikrein activity and antigen were mildly decreased in plasmas or serums of patients with chronic renal failure and nephrotic syndrome but were normal in those of patients under treatment with warfarin or suffering from SLE, rheumatoid arthritis, sarcoidosis, or HANE. Human cord serum contained a lower titer of prekallikrein antigen than adult serum. Strenuous physical exercise did not significantly change plasma prekallikrein levels.
...
PMID:Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. 65 66
We found a novel and highly selective synthetic inhibitor of
plasma kallikrein
(PK), called PKSI-527; the Ki value was 0.81 microM. PKSI-527 inhibited the bradykinin (BK) generation induced by kaolin and prolonged partial thromboplastin time (PTT). PKSI-527 prevented the decrease of fibrinogen (Fg) levels due to i.v. injection of ellagic acid in mice and ameliorated the endotoxin (ET)-induced
DIC
in rats.
...
PMID:A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC. 146 71
The purpose of the study was to explore hemostasis in children suffering from hemorrhagic vasculitis (HV) by means of the new amidolytic methods using chromogenic substrates. The patient's plasma was studied for the content of thrombin, trypsin, factor Xa, AT-III,
kallikrein
, plasmin, free heparin, urokinase, factor 3 of platelets, prothrombin and Willebrand's factor. 69 children with HV were entered into the study. All of them were examined during crises. In cutaneous HV, the content of trypsin decreased 3-fold, the content of factor Xa increased 5-fold; there was a negligible increase in the plasmin and AT-III levels; the content of
kallikrein
rose 2-fold, that of urokinase 60-fold; the release of platelet factor 3 was intensified 1.5-fold, the activity of prothrombin 3-fold. These data indicate that in cutaneous HV, blood coagulation increased. However, the signs of
disseminated intravascular coagulation
were lacking because of the high blood anticoagulant activity. In mixed HV, the phase of hypercoagulation was not made for by the blood anticoagulant activity, since the latter one was depleted. The capillary toxic nephritis may give rise to
disseminated intravascular coagulation
associated with the depletion of the anticoagulant component. The gravity of HV and its complications can be predicted according to the characteristics of the anticoagulant component of hemostasis, especially according to the levels of urokinase and AT-III.
...
PMID:[State of hemostasis in hemorrhagic vasculitis in children]. 151 26
Disseminated intravascular coagulation (DIC)
is a severe syndrome associated with generalized, intractable bleeding and multiple organ failure. Synthesized protease inhibitors such as gabexate mesilate and nafamostat mesilate show an improving effect on
DIC
, which develops by a chain reaction involving the coagulation, fibrinolysis, complement and
kallikrein
systems. Experimental
DIC
was developed in Beagle dogs by infusion of 150 U/kg tissue thromboplastin (Group I), and the improving effect of a new synthetic protease inhibitor, E-3123, was examined. The following groups of animals were treated with drugs: Group II (n = 4) was given with 5 mg/kg/hr of E-3123; group III (n = 4) was given 10 mg/kg/hr of E-3123; and group IV was given 6 mg/kg/hr of gabexate mesilate (GM). Although improvement of the hemodynamics or peripheral circulation was not apparent, a slight, but insignificant, improvement of lactate/pyruvate was noted in the treated groups. On the other hand, the hemostatic abnormalities such as prolongation of prothrombin time and activated thromboplastin time; decreases of platelet count, fibrinogen and alpha 2-antiplasmin; and increases of fibrin degradation products were significantly improved in the treated groups. These results indicate that E-3123 is effective for improving experimental
DIC
, and it is suggested that E-3123 is applicable for the treatment of clinical
DIC
.
...
PMID:[Improving effect of the synthetic protease inhibitor E-3123 on experimental DIC in dogs]. 164 70
To investigate the role
plasma kallikrein
plays in the in vivo activation of inactive renin, we measured plasma active renin, inactive renin,
kallikrein
and prekallikrein levels in 10 patients with
disseminated intravascular coagulation
(
DIC
), with 16 normal persons as controls. The plasma active renin concentration was expressed by the angiotensin I generation rate after the addition of sheep renin substrate. Plasma inactive renin was activated by trypsin. The plasma total
kallikrein
level was measured by an assay of
kallikrein
activity on synthetic substrate S-2302 after the addition of a prekallikrein activator. Plasma kallikrein was assayed by its activity on S-2302 without addition of the activator. The prekallikrein level was obtained by subtracting the
kallikrein
activity from the total
kallikrein
activity. A significant decrease in the plasma prekallikrein concentration was observed in
DIC
patients, as compared to that of controls (p less than 0.01). There was no significant difference in plasma levels of
kallikrein
, inactive renin, and the proportion of active renin between
DIC
patients and normal controls, but the active renin level was higher in
DIC
patients. There was no significant correlation between the level of
plasma kallikrein
and the proportion of active renin in either normal controls or
DIC
patients. These results are compatible with, but do not prove, the theory that
plasma kallikrein
plays a role in the in vivo activation of inactive renin.
...
PMID:Plasma active renin, inactive renin and kallikrein in patients with disseminated intravascular coagulation. 168 Sep 81
1
2
3
4
5
6
Next >>